Common Stock, par value $0.0001 per share
- Symbol
- LPCN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Lipocine Inc.
LPCNNASDAQEQUITYCurrent
Other Events
Item Other 8.01 Events On October 7, 2026, the Company announced that Health Canada had approved TLANDO ® for testosterone replacement therapy in adult males. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
Press release in this filing
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy →Registered securities in this filing
LIPOCINE INC. · 8-K · Filed 2026-10-07
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item Other
8.01 Events
On
October 7, 2026, the Company announced that Health Canada had approved TLANDO ® for testosterone replacement therapy in
adult males. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
Filed exhibits (1)
Exhibit 99.1 Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy SALT LAKE CITY, October 7, 2026 -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine’s licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). Verity Pharma holds exclusive commercial rights to TLANDO in North America and is planning for launch and commercialization in the Canadian market by the end of 2026. “Men with low testosterone in Canada have been served largely by injections and topical gels, and Health Canada’s approval of TLANDO means they will have access to a convenient oral option without needing dose titration,” said Dr. Mahesh Patel, President and Chief Executive Officer of Lipocine. “This approval represents an important step in expanding the geographic reach of TLANDO and further validates the value of Lipocine’s partnered…
Open exhibit ↗